Hers vs Midi Health: Evidence-Based Comparison

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Hers and Midi Health both offer telehealth-based weight management programs, but they differ in clinical structure, medication options, and personalization depth. Understanding these differences matters because medication response varies significantly based on individual metabolic factors and genetic predispositions, not just convenience or brand recognition.

Choosing between telehealth platforms requires more than comparing features. It demands alignment with evidence-based prescribing principles, provider oversight quality, and whether your program offers biomarker or genetic context to guide medication selection. PlexusDx emphasizes this precision-wellness approach throughout your treatment pathway.

How Hers and Midi Health Structure Clinical Care Differently

Hers operates through a network of licensed physicians and nurse practitioners who review questionnaires and medical history asynchronously. Most consultations occur via chat or brief video, with prescription decisions made within hours to days. This model prioritizes speed and accessibility over extended clinical dialogue.

Midi Health emphasizes integration with mental health and nutrition services alongside medication management. Their telehealth visits tend to be longer, with board-certified obesity medicine physicians leading consultations. This structure attempts to address behavioral and metabolic factors holistically, though actual provider qualifications vary by practitioner.

Medication Options, Dosing Protocols, and Clinical Oversight

Both platforms offer GLP-1 receptor agonists and other weight management medications, but sourcing and dosing strategies differ. Understanding where medications originate—whether from branded manufacturers or compounding pharmacies—affects cost, consistency, and access. The following table outlines typical medication pathways and clinical considerations for each platform.

Provider oversight quality directly influences medication safety and efficacy monitoring. Platforms that incorporate baseline biomarker assessment, regular weight tracking, and metabolic screening typically demonstrate better clinical outcomes than those relying on symptom reports alone.

Factor	Hers	Midi Health	Clinical Relevance
Primary GLP-1 Options	Branded medications (Wegovy, Ozempic); compounded alternatives	Branded medications; selective compounding partnerships	Branded drugs often carry higher costs; compounded options may offer bioavailability variability
Dosing Strategy	Standard titration protocols; limited dose customization	Individualized titration with nutrition input	Personalized dosing improves tolerability and response; genetic predisposition testing refines protocol selection
Provider Oversight Frequency	Initial consultation + optional follow-ups; asynchronous primarily	Initial consultation + scheduled follow-up visits	Regular monitoring supports early detection of side effects and efficacy plateau
Biomarker or Metabolic Screening	Questionnaire-based; limited lab integration	Some practices integrate fasting metabolic labs	Genetic predisposition assessment (e.g., GIPR, GLP1R variants) may inform medication choice

Personalization Through Genetic and Metabolic Context

Neither Hers nor Midi Health routinely incorporates genetic predisposition testing into their initial medication selection process. Both rely on trial-and-error approaches: start medication, monitor response, adjust as needed. This works for many patients but misses opportunities to predict which individuals may respond better to specific GLP-1 agents.

Emerging research suggests variants in GIPR, GLP1R, FTO, and MC4R genes correlate with individual metabolic patterns and GLP-1 agonist response variability. Platforms that integrate this genetic context—either independently or through partnerships—can guide more informed initial medication and dosing choices, potentially reducing adjustment cycles.

Safety, Eligibility Criteria, and Who Needs Robust Provider Oversight

Both Hers and Midi Health screen for contraindications (personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2), but screening depth and ongoing safety monitoring vary. Patients with diabetes, cardiovascular disease, or polypharmacy require more intensive provider engagement than asynchronous platforms typically provide.

Before selecting any telehealth program, discuss your metabolic history, current medications, and previous weight loss attempts with a qualified provider. Some patients benefit from genetic predisposition screening to inform medication selection. Others require regular lab work and provider contact that standard telehealth models may not support adequately.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing predispositions in peptide genetic pathways—specifically GIPR, GLP1R, FTO, and MC4R variants. This information can support a more informed conversation with your healthcare provider about whether GLP-1 therapy and which formulation aligns with your metabolic profile. Genetic predispositions inform risk and response likelihood, but should be interpreted alongside clinical history by a qualified provider.

The Precision Peptide Genetic Test does not predict exact medication response or guarantee outcomes. Instead, it reveals whether your genetic background carries predispositions toward certain metabolic or GLP-1 sensitivity patterns. When combined with metabolic assessment and provider expertise, this context helps tailor initial medication selection and dosing—reducing trial-and-error cycles compared to standard telehealth questionnaire-only approaches.

Whether you choose Hers, Midi Health, or explore compounded GLP-1 options through PlexusDx, integrating genetic context into your provider conversation strengthens decision-making. PlexusDx compounded semaglutide and tirzepatide from licensed 503A pharmacies offer an alternative to both branded and other compounding sources, paired with optional genetic predisposition screening to support precision treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main clinical difference between Hers and Midi Health telehealth programs?

Hers prioritizes rapid asynchronous consultations with minimal ongoing contact, while Midi Health emphasizes longer initial visits and multi-disciplinary support. Midi Health may integrate nutrition and mental health services more formally, though actual care intensity depends on individual practitioner and plan selection.

Do Hers and Midi Health use the same medications?

Both offer GLP-1 agonists (primarily branded versions), but sourcing, compounding partnerships, and dosing protocols differ. Hers may offer more compounded alternatives; Midi Health tends toward branded medications. Cost and consistency vary accordingly.

How does genetic testing inform GLP-1 medication selection?

Variants in GIPR, GLP1R, FTO, and MC4R genes correlate with individual metabolic response patterns. Genetic context may help guide initial medication choice and dosing strategy, potentially reducing adjustment cycles. Interpretation requires qualified provider input and should combine genetic data with clinical history.

Is asynchronous telehealth sufficient for GLP-1 therapy safety monitoring?

Asynchronous care works for stable, low-complexity patients but may be insufficient for those with diabetes, cardiovascular disease, or polypharmacy. Regular weight tracking, metabolic labs, and direct provider contact support safer prescribing and earlier detection of side effects or plateaus.

What does PlexusDx offer that differs from Hers or Midi Health?

PlexusDx provides compounded GLP-1 medications from licensed 503A pharmacies, paired with optional Precision Peptide Genetic Testing to reveal genetic predispositions in peptide pathways. This supports more personalized provider conversations without relying on branded-drug-only models or asynchronous-only care structures.

Hers vs Midi Health: Clinical Evidence & Provider Considerations